Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1600 1633 1653 1759
This examiner grants 71% of resolved cases
Within Tech Center 1700 and Art Unit 1600, Examiner Allison M Fox has handled 674 resolved cases. The allowance rate for these cases is 71.2 percent. This figure serves as a reference for the likelihood of success. A median days to allowance of 1215 defines the prosecution timeline. This duration is a consideration for applicants when managing their portfolios.
Data shows an interview lift of 35.7 percent. With 674 resolved cases, this lift indicates the impact of communication on results. The 1215 days to allowance provides a standard for pendency. The 71.2 percent allowance rate and the Art Unit 1600 designation help determine a prosecution approach for the case. These data points from Tech Center 1700 support planning for the patent process.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17863363 | LPS Priming of Stromal Cells to Generate LPS-Specific Exosome Educated Macrophages | Final Rejection | Wisconsin Alumni Research Foundation |
| 18138313 | COMPOSITIONS AND METHODS FOR OBTAINING FUNCTIONAL BASAL-LIKE CELLS | Non-Final OA | The Regents of the University of Michigan |
| 18484381 | EDITING OF CCR5 RECEPTOR GENE TO PROTECT AGAINST HIV INFECTION | Non-Final OA | President and Fellows of Harvard College |
| 18476981 | Ultrathin Interfacial Layer on a Hydrogel to Direct its Surface Properties and Cell Adhesion | Non-Final OA | THE TRUSTEES OF PRINCETON UNIVERSITY |
| 18401111 | NERVE GRAFTS AND METHODS OF PREPARATION THEREOF | Non-Final OA | Axogen Corporation |
| 18753253 | BONE AUGMENTATION UTILIZING MUSCLE-DERIVED PROGENITOR COMPOSITIONS, AND TREATMENTS THEREOF | Non-Final OA | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 18316001 | Artificial Cells and Delivery Devices for Use in Tissue Engineering, and Related Methods | Non-Final OA | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 18583308 | DECELLULARIZED MUSCLE MATRIX | Non-Final OA | LifeCell Corporation |
| 18386832 | METHODS FOR MAKING ACELLULAR TISSUE MATRICES | Non-Final OA | LifeCell Corporation |
| 17486855 | ABCB5(+) STEM CELLS FOR TREATING OCULAR DISEASE | Non-Final OA | Children's Medical Center Corporation |
| 17999583 | FIBROBLAST THERAPY FOR PREVENTION AND REVERSION OF ANEURYSMS | Non-Final OA | FIGENE, LLC |
| 18542272 | COMPOSITION AND METHOD OF USE OF THE SAME FOR PRESERVING CELLS FOR ANALYSIS | Non-Final OA | Chryos, LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy